These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

132 related articles for article (PubMed ID: 15285706)

  • 1. Mucosal AIDS vaccines: current status and future directions.
    Belyakov IM; Ahlers JD; Berzofsky JA
    Expert Rev Vaccines; 2004 Aug; 3(4 Suppl):S65-73. PubMed ID: 15285706
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Mucosal immunity and HIV-1 infection: applications for mucosal AIDS vaccine development.
    Belyakov IM; Ahlers JD
    Curr Top Microbiol Immunol; 2012; 354():157-79. PubMed ID: 21203884
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Simultaneous approach using systemic, mucosal and transcutaneous routes of immunization for development of protective HIV-1 vaccines.
    Belyakov IM; Ahlers JD
    Curr Med Chem; 2011; 18(26):3953-62. PubMed ID: 21824096
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Impact of vaccine-induced mucosal high-avidity CD8+ CTLs in delay of AIDS viral dissemination from mucosa.
    Belyakov IM; Kuznetsov VA; Kelsall B; Klinman D; Moniuszko M; Lemon M; Markham PD; Pal R; Clements JD; Lewis MG; Strober W; Franchini G; Berzofsky JA
    Blood; 2006 Apr; 107(8):3258-64. PubMed ID: 16373659
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A novel functional CTL avidity/activity compartmentalization to the site of mucosal immunization contributes to protection of macaques against simian/human immunodeficiency viral depletion of mucosal CD4+ T cells.
    Belyakov IM; Isakov D; Zhu Q; Dzutsev A; Berzofsky JA
    J Immunol; 2007 Jun; 178(11):7211-21. PubMed ID: 17513770
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Functional CD8+ CTLs in mucosal sites and HIV infection: moving forward toward a mucosal AIDS vaccine.
    Belyakov IM; Ahlers JD
    Trends Immunol; 2008 Nov; 29(11):574-85. PubMed ID: 18838298
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Natural killer T cell and TLR9 agonists as mucosal adjuvants for sublingual vaccination with clade C HIV-1 envelope protein.
    Singh S; Yang G; Byrareddy SN; Barry MA; Sastry KJ
    Vaccine; 2014 Dec; 32(51):6934-6940. PubMed ID: 25444819
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Induction of HIV immunity in the genital tract after intranasal delivery of a MVA vector: enhanced immunogenicity after DNA prime-modified vaccinia virus Ankara boost immunization schedule.
    Gherardi MM; Pérez-Jiménez E; Nájera JL; Esteban M
    J Immunol; 2004 May; 172(10):6209-20. PubMed ID: 15128809
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Immunobiology of mucosal HIV infection and the basis for development of a new generation of mucosal AIDS vaccines.
    Belyakov IM; Berzofsky JA
    Immunity; 2004 Mar; 20(3):247-53. PubMed ID: 15030769
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Strategies for optimizing targeting and delivery of mucosal HIV vaccines.
    Ahlers JD; Belyakov IM
    Eur J Immunol; 2009 Oct; 39(10):2657-69. PubMed ID: 19609978
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Mucosal AIDS vaccine reduces disease and viral load in gut reservoir and blood after mucosal infection of macaques.
    Belyakov IM; Hel Z; Kelsall B; Kuznetsov VA; Ahlers JD; Nacsa J; Watkins DI; Allen TM; Sette A; Altman J; Woodward R; Markham PD; Clements JD; Franchini G; Strober W; Berzofsky JA
    Nat Med; 2001 Dec; 7(12):1320-6. PubMed ID: 11726972
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Current efforts on generation of optimal immune responses against HIV through mucosal immunisations.
    Vajdy M
    Drugs R D; 2006; 7(5):267-88. PubMed ID: 16922589
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Induction of intestinal immunity by mucosal vaccines as a means of controlling HIV infection.
    Poles J; Alvarez Y; Hioe CE
    AIDS Res Hum Retroviruses; 2014 Nov; 30(11):1027-40. PubMed ID: 25354023
    [TBL] [Abstract][Full Text] [Related]  

  • 14. CD8+ T-cell-mediated cross-clade protection in the genital tract following intranasal immunization with inactivated human immunodeficiency virus antigen plus CpG oligodeoxynucleotides.
    Jiang JQ; Patrick A; Moss RB; Rosenthal KL
    J Virol; 2005 Jan; 79(1):393-400. PubMed ID: 15596832
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Membrane-anchored CCL20 augments HIV Env-specific mucosal immune responses.
    Sun X; Zhang H; Xu S; Shi L; Dong J; Gao D; Chen Y; Feng H
    Virol J; 2017 Aug; 14(1):163. PubMed ID: 28830557
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Mucosal HIV vaccines: where are we now?
    Stevceva L; Strober W
    Curr HIV Res; 2004 Jan; 2(1):1-10. PubMed ID: 15053336
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Induction of mucosal and systemic antibody responses against the HIV coreceptor CCR5 upon intramuscular immunization and aerosol delivery of a virus-like particle based vaccine.
    Hunter Z; Smyth HD; Durfee P; Chackerian B
    Vaccine; 2009 Dec; 28(2):403-14. PubMed ID: 19849995
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Interplay of cytokines and adjuvants in the regulation of mucosal and systemic HIV-specific CTL.
    Belyakov IM; Ahlers JD; Clements JD; Strober W; Berzofsky JA
    J Immunol; 2000 Dec; 165(11):6454-62. PubMed ID: 11086085
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Evaluation of fowlpox-vaccinia virus prime-boost vaccine strategies for high-level mucosal and systemic immunity against HIV-1.
    Ranasinghe C; Medveczky JC; Woltring D; Gao K; Thomson S; Coupar BE; Boyle DB; Ramsay AJ; Ramshaw IA
    Vaccine; 2006 Jul; 24(31-32):5881-95. PubMed ID: 16759767
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Mucosal HIV transmission and vaccination strategies through oral compared with vaginal and rectal routes.
    Yu M; Vajdy M
    Expert Opin Biol Ther; 2010 Aug; 10(8):1181-95. PubMed ID: 20624114
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.